Multimodality in vivo Molecular Imaging for Prostate PDT

前列腺 PDT 的多模态体内分子成像

• 批准号: 7081117
• 负责人: BAOWEI FEI
• 金额: $ 16.79万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7081117
• 关键词: athymic mouse; bioimaging /biomedical imaging; biomarker; disease /disorder model; magnetic resonance imaging; male; molecular /cellular imaging; neoplasm /cancer imaging; neoplasm /cancer photoradiation therapy; neoplasm /cancer transplantation; nonhuman therapy evaluation; positron emission tomography; prostate neoplasms; technology /technique development; xenotransplantation

DESCRIPTION (provided by applicant): Prostate cancer is the second leading cause of cancer mortality in American men. The long-term objective of this research is to develop novel multimodality molecular imaging techniques for improved early detection and image-guided therapy for prostate cancer. At our institution, a second generation photosensitizing drug PC 4 has been evaluated for photodynamic therapy (PDT) at the Case Comprehensive Cancer Center. This drug is currently undergoing pre-clinical mechanistic studies and two Phase I clinical trials for the treatment of dermal cancers, including cancers that are metastatic to the skin. Members of this investigating team have already proven the efficacy of PC 4-PDT for the treatment of breast, ovarian, and colon cancer in animal models. In addition, a co-investigator, Dr. Nancy Oleinick found that PC 4-PDT induces apoptosis in prostate cancer cells in vitro. We are now extending this relatively new treatment modality for prostate cancer therapy. In the R21 phase, we will perform in vivo PDT to treat human prostate cancer xenografts in a mouse model. State-of-the-art in vivo molecular imaging techniques will be developed to assess the PDT efficacy. Image fusion and registration of various imaging modalities and quantitative image analysis methods will be developed to combine functional biochemical images with high-resolution anatomic images. An early image-based surrogate biomarker of the tumor response to PDT will be identified to predict the success of the therapy. The noninvasive imaging techniques to be created from this study can be applied to other cancers. They can be used to detect very early cancers, optimize treatment planning for individualized therapy, utilize image-guided minimally invasive therapy, and monitor the therapeutic efficacy. The proposed imaging strategy has great potential to enhance public health by improving diagnosis and therapy of cancer.

描述（由申请人提供）：前列腺癌是美国男性癌症死亡的第二大原因。这项研究的长期目标是开发新型多模态分子成像技术，以改善前列腺癌的早期检测和图像引导治疗。在我们机构，第二代光敏药物 PC 4 已在凯斯综合癌症中心进行光动力疗法 (PDT) 评估。该药物目前正在进行临床前机制研究和两项治疗皮肤癌（包括转移至皮肤的癌症）的 I 期临床试验。该研究小组的成员已经在动物模型中证明了 PC 4-PDT 治疗乳腺癌、卵巢癌和结肠癌的功效。此外，共同研究员 Nancy Oleinick 博士发现 PC 4-PDT 在体外诱导前列腺癌细胞凋亡。我们现在正在将这种相对较新的治疗方式扩展到前列腺癌治疗。在R21阶段，我们将进行体内PDT来治疗小鼠模型中的人类前列腺癌异种移植物。将开发最先进的体内分子成像技术来评估 PDT 疗效。将开发各种成像模式的图像融合和配准以及定量图像分析方法，以将功能生化图像与高分辨率解剖图像结合起来。将确定肿瘤对 PDT 反应的早期基于图像的替代生物标志物，以预测治疗的成功。这项研究创建的非侵入性成像技术可以应用于其他癌症。它们可用于检测非常早期的癌症、优化个体化治疗的治疗计划、利用图像引导的微创治疗以及监测治疗效果。所提出的成像策略具有通过改善癌症诊断和治疗来增强公众健康的巨大潜力。